Englander Institute for Precision Medicine

Publications

Found 785 results
Author Title Type [ Year(Asc)]
2021
Aeppli S, Schmaus M, Eisen T, Escudier B, Grünwald V, Larkin J, McDermott D, Oldenburg J, Porta C, Rini BI et al..  2021.  First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts.. ESMO Open. 6(1):100030.
Shohdy KS, Bareja R, Sigouros M, Wilkes DC, Dorsaint P, Manohar J, Bockelman D, Xiang JZ, Kim R, Ohara K et al..  2021.  Functional comparison of exome capture-based methods for transcriptomic profiling of formalin-fixed paraffin-embedded tumors.. NPJ Genom Med. 6(1):66.
Mukhopadhyay C, Yang C, Xu L, Liu D, Wang Y, Huang D, Deonarine LDayal, Cyrta J, Davicioni E, Sboner A et al..  2021.  G3BP1 inhibits Cul3 to amplify AR signaling and promote prostate cancer.. Nat Commun. 12(1):6662.
Wolujewicz P, Aguiar-Pulido V, AbdelAleem A, Nair V, Thareja G, Suhre K, Shaw GM, Finnell RH, Elemento O, M Ross E.  2021.  Genome-wide investigation identifies a rare copy-number variant burden associated with human spina bifida.. Genet Med. 23(7):1211-1218.
Merseburger AS, Waldron N, Ribal MJ, Heidenreich A, Perner S, Fizazi K, Sternberg CN, Mateo J, Wirth MP, Castro E et al..  2021.  Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.. Eur Urol. 79(4):519-529.
Davis MB.  2021.  Genomics and Cancer Disparities: The Justice and Power of Inclusion.. Cancer Discov. 11(4):805-809.
Suhre K, Sarwath H, Engelke R, Sohail MUmar, Cho SJung, Whalen W, Alvarez-Mulett S, Krumsiek J, Choi AMK, Schmidt F.  2021.  Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies.. Front Immunol. 12:781100.
Han Y, Duan X, Yang L, Nilsson-Payant BE, Wang P, Duan F, Tang X, Yaron TM, Zhang T, Uhl S et al..  2021.  Identification of SARS-CoV-2 inhibitors using lung and colonic organoids.. Nature. 589(7841):270-275.
Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN.  2021.  Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.. J Clin Invest. 131(5)
Fornarini G, Rebuzzi SE, Banna GL, Calabrò F, Scandurra G, De Giorgi U, Masini C, Baldessari C, Naglieri E, Caserta C et al..  2021.  Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort.. ESMO Open. 6(3):100118.
Sato A, Buqué A, Yamazaki T, Bloy N, Petroni G, Galluzzi L.  2021.  Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells.. STAR Protoc. 2(2):100488.
Petroni G, Kroemer G, Galluzzi L.  2021.  Immunogenic Therapies Drive CAR T Cells towards Superior Efficacy.. Trends Cancer. 7(3):179-181.
De Martino M, Vanpouille-Box C, Galluzzi L.  2021.  Immunological barriers to immunotherapy in primary and metastatic breast cancer.. EMBO Mol Med. 13(8):e14393.
Fucikova J, Coosemans A, Orsulic S, Cibula D, Vergote I, Galluzzi L, Spisek R.  2021.  Immunological configuration of ovarian carcinoma: features and impact on disease outcome.. J Immunother Cancer. 9(10)
Galluzzi L, Garg AD.  2021.  Immunology of Cell Death in Cancer Immunotherapy.. Cells. 10(5)
Petroni G, Buqué A, Zitvogel L, Kroemer G, Galluzzi L.  2021.  Immunomodulation by targeted anticancer agents.. Cancer Cell. 39(3):310-345.
Tombal B, Stenzl A, Cella D, Loriot Y, Armstrong AJ, Fizazi K, Beer T, Sternberg CN, Hussain M, Ivanescu C et al..  2021.  The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials.. Cancers (Basel). 13(23)
Petroni G, Galluzzi L.  2021.  Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents.. Oncoimmunology. 10(1):1889101.
Zoughbi WAl, Kim D, Alperstein SAnn, Ohara K, Manohar J, Greco N, Khani F, Robinson BD, Rao RA, Elemento O et al..  2021.  Incorporating cytologic adequacy assessment into precision oncology workflow using telepathology: An institutional experience.. Cancer Cytopathol. 129(11):874-883.
Ciccolella S, Ricketts C, Gomez MSoto, Patterson M, Silverbush D, Bonizzoni P, Hajirasouliha I, Vedova GDella.  2021.  Inferring cancer progression from Single-Cell Sequencing while allowing mutation losses.. Bioinformatics. 37(3):326-333.
Beg S, Bareja R, Ohara K, Eng KWha, Wilkes DC, Pisapia DJ, Zoughbi WAl, Kudman S, Zhang W, Rao R et al..  2021.  Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.. Transl Oncol. 14(1):100944.
Vitale I, Shema E, Loi S, Galluzzi L.  2021.  Intratumoral heterogeneity in cancer progression and response to immunotherapy.. Nat Med. 27(2):212-224.
Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, Massard C, Matsubara N, Alekseev B, Parnis F et al..  2021.  Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.. Lancet. 398(10295):131-142.
Buqué A, Galluzzi L, Kroemer G.  2021.  Ketosis versus carbotoxicity - metabolism determines the outcome of cancer immunotherapy.. Mol Cell Oncol. 8(1):1868266.
Marderstein AR, Davenport ER, Kulm S, Van Hout CV, Elemento O, Clark AG.  2021.  Leveraging phenotypic variability to identify genetic interactions in human phenotypes.. Am J Hum Genet. 108(1):49-67.